Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR
Latest press releases and news stories
Go to news archive

03/03/2025
Press release
AAD 2025: Galderma to present extensive updates from across its dermatology portfolio, demonstrating its category leadership and strong momentum

02/03/2025
News story
AAD 2025: Galderma’s Scientific Presentations

18/02/2025
Press release
Galderma’s Nemluvio® (nemolizumab) granted marketing authorization in the United Kingdom and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis

14/02/2025
Press release
Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis
Galderma Annual reviews